Overview and Scope
5-alpha reductase deficiency is a disorder which affects male sexual development both before and during puberty. Dihydrotestosterone, a crucial hormone for male sexual development, is not sufficiently produced in people suffering from 5-alpha reductase deficiency.
Sizing and Forecast
The 5-alpha reductase deficiency market size has grown strongly in recent years. It will grow from $1.29 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to research and development, regulatory landscape, healthcare infrastructure, increased awareness and education, health insurance coverage.
The 5-alpha reductase deficiency market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to innovations in therapeutics, genetic research advances, precision medicine, global health initiatives, integration of gene therapies. Major trends in the forecast period include advancements in treatment options, diagnostic innovations, patient-centric approaches, regulatory landscape, market access and affordability.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report
Segmentation & Regional Insights
The 5-alpha reductase deficiency market covered in this report is segmented –
1) By Diagnosis: Chromosome Analysis, Gene Sequencing, Hormone Tests, Imaging Tests, Genetic Screening, Other Diagnosis
2) By Treatment: Surgery, Vaginoplasty, Feminizing Genitoplasty, Hormone Replacement Therapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users
North America was the largest region in the 5-alpha reductase deficiency market in 2023. The regions covered in the 5-alpha reductase deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=9438&type=smp
Major Driver Impacting Market Growth
The growing number of research and development activities in genomics is significantly contributing to the growth of the 5-alpha reductase deficiency market. Genomics refers to studying a person’s whole gene pool (genome), including how those genes interact with one another and with their environment. Genomics is used to diagnose 5-alpha reductase deficiency by identifying specific genetic mutations responsible for the disorder. Thus, research and development activities in genomics will aid in discovering and treating the disorder. For instance, in July 2022, according to the ‘Accelerating Access to Genomics for Global Health’ report issued by the World Health Organization (WHO), a Switzerland-based specialized health agency of the United Nations, the percentage of nations equipped to conduct genomic surveillance rose from 54% to 68% between March 2021 and January 2022. Therefore, the growing number of research and development activities in genomics will drive the 5-alpha reductase deficiency market.
Key Industry Players
Major companies operating in the 5-alpha reductase deficiency market are adopting a strategic partnership approach, aiming to commercialize Finjuve (finasteride) throughout the Middle East and North Africa. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in November 2021, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, announced a licensing agreement with Almirall S.A. to bring Finjuve to market in a few MENA (Middle East and North Africa) countries. Finjuve is a finasteride spray that is licensed for the medical management of androgenetic alopecia in Germany, Italy, Luxembourg, and Portugal. According to the terms of the license deal, Hikma will be in charge of product registration and commercialization in specific MENA regions, while Almirall will be in charge of product supply. This agreement expands Hikma’s presence in dermatology, a crucial therapeutic area for Hikma, and adds a unique product to the portfolio. Almirall S.A. is a Spain-based pharmaceutical company.
The 5-alpha reductase deficiency market report table of contents includes:
1. Executive Summary
2. 5-Alpha Reductase Deficiency Characteristics
3. 5-Alpha Reductase Deficiency Trends And Strategies
4. 5-Alpha Reductase Deficiency – Macro Economic Scenario
5. Global 5-Alpha Reductase Deficiency Size and Growth
…..
32. Global 5-Alpha Reductase Deficiency Competitive Benchmarking
33. Global 5-Alpha Reductase Deficiency Competitive Dashboard
34. Key Mergers And Acquisitions In The 5-Alpha Reductase Deficiency
35. 5-Alpha Reductase Deficiency Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
